Radiofrequency Ablation Devices Are Advancing With Increasing Technological Development and Research Activities
There are many questions patients and physicians have about Radiofrequency Ablation Devices. This procedure involves the use of a balloon catheter which inflates to three psi after the patient steps on the pedal. This balloon is inflated to the appropriate diameter for the patient. Then, a small radiofrequency energy source is injected through the electrodes, resulting in circumferential mucosal ablation over a distance of four cm.
Using a small RF generator, a large dispersive electrode, and an electrode needle an alternating electric field is generated within the patient's tissue. Due to the high electrical resistance of the tissue, ions within the target tissue are agitated. This leads to frictional heat in the area around the electrode, which damages the tissue. The procedure has been used to destroy a variety of tumors. This treatment is becoming increasingly common.
Furthermore, Radiofrequency Ablation Devices Market are inexpensive and provide quick relief. These devices such as the CF catheters and PVI with additional lesion sets are available in many hospitals around the world. For the patient, the cost-effectiveness of this treatment makes it an excellent choice. RFA is performed through a catheter that is inflated to three psi. Serial measurements are made along the segment of interest to determine the diameter of the esophagus. The treatment balloon is then selected based on the smallest diameter. The recommended settings are 12 J/cm2 for BEs that are dysplastic and 10 J/cm2 for those without. The treatment is generally accompanied by endoscopic monitoring.
Radiofrequency Ablation Devices are becoming increasingly popular among cancer patients. The technology is safe and effective, and has the potential to treat a wide variety of cancers. RF devices are currently used to treat non-small cell lung cancer (NSCL), which accounts for the majority of cancer cases worldwide. However, some concerns about RF electrode positioning have led to the emergence of a new technique for treating this disease. Further research is needed to better determine the most effective techniques for treating hepatic tumors. In May 2021, Galaxy Medical entered into distribution agreement with Japan Lifeline for the ALPHA1 ablation catheter in the U.S. developed by Japan Lifeline to use with the Galaxy CENTAURI Pulsed Electric Field (PEF) System.

Comments
Post a Comment